Saturday, December 26, 2009

Definity


Definity is a brand name of perflutren, approved by the FDA in the following formulation(s):


DEFINITY (perflutren - injectable; intravenous)



  • Manufacturer: LANTHEUS MEDCL

    Approval date: July 31, 2001

    Strength(s): 6.52MG/ML [RLD]

Has a generic version of Definity been approved?


No. There is currently no therapeutically equivalent version of Definity available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
    Patent 5,527,521
    Issued: June 18, 1996
    Inventor(s): Unger; Evan C.
    Assignee(s): ImaRx Pharmaceutical Corp.
    Substantially homogeneous aqueous suspensions of low density microspheres are presented as contrast media for imaging the gastrointestinal tract and other body cavities using computed tomography. In one embodiment, the low density microspheres are gas-filled. With computed tomography, the contrast media serve to change the relative density of certain areas within the gastrointestinal tract and other body cavities, and improve the overall diagnostic efficacy of this imaging method.
    Patent expiration dates:

    • February 22, 2015
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
      ✓ 
      Drug product




  • Method of preparing gas and gaseous precursor-filled microspheres
    Patent 5,585,112
    Issued: December 17, 1996
    Inventor(s): Unger; Evan C. & Fritz; Thomas A. & Matsunaga; Terry & Ramaswami; VaradaRajan & Yellowhair; David & Wu; Guanli
    Assignee(s): ImaRx Pharmaceutical Corp.
    Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.
    Patent expiration dates:

    • December 17, 2013
      ✓ 
      Drug product




  • Methods for diagnostic imaging by regulating the administration rate of a contrast agent
    Patent 6,033,645
    Issued: March 7, 2000
    Inventor(s): Unger; Evan C. & Matsunaga; Terry & Fritz; Thomas A. & Ramaswami; Varadarajan
    Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region. The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING



See also...

  • Definity Consumer Information (Wolters Kluwer)
  • Definity Advanced Consumer Information (Micromedex)
  • Perflutren (Lipid Microspheres) Consumer Information (Wolters Kluwer)
  • Perflutren (Protein-Type A Microspheres) Consumer Information (Wolters Kluwer)
  • Perflutren lipid microsphere Intravenous Advanced Consumer Information (Micromedex)
  • Perflutren protein type a microsphere Intravenous Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Friday, December 25, 2009

Cough Medications


Definition of Cough: A rapid expulsion of air from the lungs typically in order to clear the lung airways of fluids, mucus, or material.

Drugs associated with Cough

The following drugs and medications are in some way related to, or used in the treatment of Cough. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Cough

  • Cough and Nasal Congestion (596 drugs)

Learn more about Cough

Medical Encyclopedia:

  • Cough




Drug List:

Posted by at No comments:
Labels:

Tuesday, December 22, 2009

Neluos




Neluos may be available in the countries listed below.


Ingredient matches for Neluos



Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Neluos in the following countries:


  • Japan

International Drug Name Search

Posted by at No comments:
Labels:

Alvesco


Alvesco is a brand name of ciclesonide, approved by the FDA in the following formulation(s):


ALVESCO (ciclesonide - aerosol, metered; inhalation)



  • Manufacturer: NYCOMED US

    Approval date: January 10, 2008

    Strength(s): 0.08MG/INH, 0.16MG/INH [RLD]

Has a generic version of Alvesco been approved?


No. There is currently no therapeutically equivalent version of Alvesco available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alvesco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
    Patent 5,482,934
    Issued: January 9, 1996
    Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
    Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
    The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.
    Patent expiration dates:

    • October 24, 2017
      ✓ 
      Patent use: METHOD OF TREATING INFLAMMATORY CONDITIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Medicinal aerosol formulations
    Patent 5,605,674
    Issued: February 25, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:

    • February 25, 2014
      ✓ 
      Drug product




  • Medicinal aerosol formulations
    Patent 5,683,677
    Issued: November 4, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:

    • November 4, 2014
      ✓ 
      Drug product




  • Seal configuration for aerosol canister
    Patent 5,775,321
    Issued: July 7, 1998
    Inventor(s): Alband; Todd D.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
    Patent expiration dates:

    • July 7, 2015
      ✓ 
      Drug product




  • Device for delivering an aerosol
    Patent 6,006,745
    Issued: December 28, 1999
    Inventor(s): Marecki; Paul E.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
    Patent expiration dates:

    • December 28, 2016
      ✓ 
      Drug product




  • Seal configuration for aerosol canister
    Patent 6,036,942
    Issued: March 14, 2000
    Inventor(s): Alband; Todd D.
    Assignee(s): 3M Innovative Properties Company
    An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.
    Patent expiration dates:

    • April 30, 2013
      ✓ 
      Drug product




  • Medicinal aerosol products containing formulations of ciclesonide and related steroids
    Patent 6,120,752
    Issued: September 19, 2000
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company
    Byk Gulden Lomberg Chemische Fabrik GmbH
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:

    • May 13, 2018
      ✓ 
      Drug product




  • Medicinal aerosol formulation of ciclesonide and related compounds
    Patent 6,264,923
    Issued: July 24, 2001
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:

    • May 13, 2018
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 10, 2011 - NEW DOSAGE FORM

    • October 20, 2011 - NEW CHEMICAL ENTITY

See also...

  • Alvesco Consumer Information (Drugs.com)
  • Alvesco Aerosol Consumer Information (Wolters Kluwer)
  • Alvesco HFA inhalation Consumer Information (Cerner Multum)
  • Alvesco inhalation Consumer Information (Cerner Multum)
  • Alvesco Advanced Consumer Information (Micromedex)
  • Ciclesonide Aerosol Consumer Information (Wolters Kluwer)
  • Ciclesonide inhalation Consumer Information (Cerner Multum)
  • Ciclesonide Inhalation Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Friday, December 18, 2009

Defencare




Defencare may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Defencare



Permethrin

Permethrin is reported as an ingredient of Defencare in the following countries:


  • Germany

  • Netherlands

  • United Kingdom

International Drug Name Search

Posted by at No comments:
Labels:

Thursday, December 17, 2009

Selsun Gold




Ingredient matches for Selsun Gold



Selenium Sulfide

Selenium Sulfide is reported as an ingredient of Selsun Gold in the following countries:


  • United States

International Drug Name Search

Posted by at No comments:
Labels:

Wednesday, December 9, 2009

Humalog Mix 75 / 25


See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25 KwikPen, Generic Humalog Mix 75/25 Pen


Humalog Mix 75/25 is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):


HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: December 22, 1999

    Strength(s): 75 UNITS/ML;25 UNITS/ML [RLD]

Has a generic version of Humalog Mix 75/25 been approved?


No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Monomeric insulin analog formulations
    Patent 5,461,031
    Issued: October 24, 1995
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analog formulations
    Patent 5,474,978
    Issued: December 12, 1995
    Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
    Assignee(s): Eli Lilly and Company
    The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analogs modified at position 29 of the B chain
    Patent 5,514,646
    Issued: May 7, 1996
    Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
    Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
    Patent expiration dates:

    • May 7, 2013




  • Monomeric insulin analog formulations
    Patent 5,747,642
    Issued: May 5, 1998
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014



See also...

  • HumaLog Mix 75/25 Vials Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Pens Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Consumer Information (Cerner Multum)
  • Humalog Mix 75/25 Advanced Consumer Information (Micromedex)
  • Humalog Mix Consumer Information (Drugs.com)
  • Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
  • Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
  • Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
  • Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)